- Exchange: OTC BB
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
TG Therapeutics Inc
+ Add to WatchlistTGTX:US
5.4800 USD 0.1700 3.01%As of 20:10:00 ET on 05/22/2013.
Snapshot for TG Therapeutics Inc (TGTX)
| Open: | 5.6500 | Day's Range: | 5.0600 - 5.6700 | Volume: | 120,987 |
|---|---|---|---|---|---|
| Previous Close: | 5.6500 | 52wk Range: | 1.8200 - 6.7500 | 1-Yr Rtn: | -11.04% |
Key Statistics for TGTX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.6200 |
| Est. EPS (USD) (12/2013) | -0.6800 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 144.25 |
| Shares Outstanding (M) | 26.32 |
| 30 Day Average Volume | 29,344 |
| Price/Book (mrq) | 9.0994 |
| Price/Sale (ttm) | 2,034.0950 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for TGTX
Company Profile & Key Executives for TGTX
TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.
| Michael S Weiss "Mike"Chairman/Pres/Interim CEO | Sean A PowerCFO/Treasurer/Secretary |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
TGTX News
-
Industry News
No stories found
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page